In conclusion, we have found that the occurrence of parthanatos in endotoxemia and erlotinib can significantly mitigate LPS-induced parthanatos in vivo and in vitro via suppressing cell surface TLR4 expression. This evidence concerns the gene TLR4 and serum lipopolysaccharide activity.